Author
VELLAS, BRUNO - Gerontopole De Toulouse Center Hospital University | |
FIELDING, ROGER - Jean Mayer Human Nutrition Research Center On Aging At Tufts University | |
BENS, CYNTHIA - Aging In Motion (AIM) | |
BERNABEI, ROBERTO - Catholic University Of The Sacred Heart Italy | |
CAWTHON, PEGGY - California Pacific Medical Center | |
CEDERHOLM, TOMMY - Uppsala University | |
CRUZ-JENTOFT, ALPHONSO - Instituto Ramon Y Cajal De Investigacion Sanitaria (IRYCIS) | |
DEL SIGNORE, SUSANNA - Sorbonne Universities, Paris | |
DONAHUE, STEPHEN - Regeneron Pharmaceuticals, Inc | |
MORLEY, JOHN - St Louis University | |
PAHOR, MARCO - University Of Florida | |
REGINSTER, JEAN-YVES - University Of Liege | |
RODRIGUEZ MANAS, LEOCADIO - University Hospital Of Getafe | |
ROLLAND, YVES - La Grave Hospital | |
ROUBENOFF, RONENN - Novartis Institutes | |
SINCLAIR, ALAN - University Of Bedfordshire | |
CESARI, MATTEO - University Hospital Center Of Toulouse |
Submitted to: The Journal of Frailty and Aging
Publication Type: Review Article Publication Acceptance Date: 8/17/2017 Publication Date: 8/23/2017 Citation: Vellas, B., Fielding, R.A., Bens, C., Bernabei, R., Cawthon, P.M., Cederholm, T., Cruz-Jentoft, A.J., Del Signore, S., Donahue, S., Morley, J., Pahor, M., Reginster, J., Rodriguez Manas, L., Rolland, Y., Roubenoff, R., Sinclair, A., Cesari, M. 2017. Implications of ICD-10 for sarcopenia clinical practice and clinical trials: report by the International Conference on Frailty and Sarcopenia Research Task Force. The Journal of Frailty and Aging. 7(1):2-9. https://doi.org/10.14283/jfa.2017.30. DOI: https://doi.org/10.14283/jfa.2017.30 Interpretive Summary: Technical Abstract: Establishment of an ICD-10-CM code for sarcopenia in 2016 was an important step towards reaching international consensus on the need for a nosological framework of age-related skeletal muscle decline. The International Conference on Frailty and Sarcopenia Research Task Force met in April 2017 to discuss the meaning, significance, and barriers to the implementation of the new code as well as strategies to accelerate development of new therapies. Analyses by the Sarcopenia Definitions and Outcomes Consortium are underway to develop quantitative definitions of sarcopenia. A consensus conference is planned to evaluate this analysis. The Task Force also discussed lessons learned from sarcopenia trials that could be applied to future trials, as well as lessons from the osteoporosis field, a clinical condition with many constructs similar to sarcopenia and for which ad hoc treatments have been developed and approved by regulatory agencies. |